Work

Myelofibrosis end points and self-evident truths

Year: 2026

Type: article

Abstract: In this issue of Blood, Pemmaraju et al 1 identify, through TRANSFORM-1, both the promise and limits of combining navitoclax with ruxolitinib, sharpening a central challenge in myelofibrosis (MF) drug development: how best to measure meaningful clinical benefit.

Source: Blood

DOI: 10.1182/blood.2026035301

Authors: Pankit Vachhani, Raajit K. Rampal

Institutions: University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Pfizer